159 related articles for article (PubMed ID: 12086907)
1. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.
Hosch SB; Scheunemann P; Lüth M; Inndorf S; Stoecklein NH; Erbersdobler A; Rehders A; Gundlach M; Knoefel WT; Izbicki JR
J Gastrointest Surg; 2001; 5(6):673-9. PubMed ID: 12086907
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
3. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
Gelderman KA; Blok VT; Fleuren GJ; Gorter A
Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
[TBL] [Abstract][Full Text] [Related]
5. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
7. High-level co-expression of complement regulators on vascular endothelium in transgenic mice: CD55 and CD59 provide greater protection from human complement-mediated injury than CD59 alone.
Cowan PJ; Shinkel TA; Aminian A; Romanella M; Wigley PL; Lonie AJ; Nottle MB; Pearse MJ; d'Apice AJ
Xenotransplantation; 1998 Aug; 5(3):184-90. PubMed ID: 9741456
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.
Spiller OB; Criado-García O; Rodríguez De Córdoba S; Morgan BP
Clin Exp Immunol; 2000 Aug; 121(2):234-41. PubMed ID: 10931136
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.
Zhao WP; Zhu B; Duan YZ; Chen ZT
Oncol Rep; 2009 Jun; 21(6):1405-11. PubMed ID: 19424617
[TBL] [Abstract][Full Text] [Related]
10. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
[TBL] [Abstract][Full Text] [Related]
11. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
12. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
14. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
[TBL] [Abstract][Full Text] [Related]
15. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
Iborra A; Mayorga M; Llobet N; Martínez P
Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
[TBL] [Abstract][Full Text] [Related]
16. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
[TBL] [Abstract][Full Text] [Related]
17. Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease.
Mishra N; Mohata M; Narang R; Lakshmy R; Hazarika A; Pandey RM; Das N; Luthra K
Front Immunol; 2019; 10():2072. PubMed ID: 31555286
[TBL] [Abstract][Full Text] [Related]
18. Loss of CD55 is associated with aggressive breast tumors.
Madjd Z; Durrant LG; Bradley R; Spendlove I; Ellis IO; Pinder SE
Clin Cancer Res; 2004 Apr; 10(8):2797-803. PubMed ID: 15102687
[TBL] [Abstract][Full Text] [Related]
19. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus.
Richaud-Patin Y; Pérez-Romano B; Carrillo-Maravilla E; Rodriguez AB; Simon AJ; Cabiedes J; Jakez-Ocampo J; Llorente L; Ruiz-Argüelles A
Immunol Lett; 2003 Aug; 88(2):95-9. PubMed ID: 12880676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]